From 1987 to 1995, 22 children with refractory solid tumors entered a phase II study of high-dose thiotepa (HDT) (900 mg/m 2 ) followed by stem cell transplantation (SCT) in the Pediatrics Department of the Institut Gustave Roussy. Tumor types were rhabdomyosarcoma (eight), osteosarcoma (seven), neuroblastoma (three), Ewing's sarcoma (three) and Burkitt's lymphoma (one). Before HDT, all had been extensively treated with conventional chemotherapy, surgical resection of the primary tumor (13/22) and of metastases (6/22), and radiotherapy of the primary tumor in three patients. All had measurable disease, at the site of the primary tumor (3 patients), of the metastases (9 patients) or both (10 patients). Toxicity from the HDT was severe but acceptable. No toxicity-related death occurred. The median duration of neutropenia and thrombocytopenia was 18 days (5-37) and 30 days (7-377), respectively. Septicemia was documented in four patients. Severe diarrhea was observed in seven patients. Mild hepatic toxicity occurred 18 times. No CR and 11/22 PR were documented: osteosarcoma 4/7, rhabdomyosarcoma 4/8, Ewing's sarcoma 2/3; 1/1 Burkitt's lymphoma progressed. We conclude that at a dose of 900 mg/m 2 followed by SCT support in these heavily pretreated children, the main toxicity induced by thiotepa was digestive. The response rate observed, especially in sarcoma, is particularly encouraging. Thiotepa should be further evaluated in HDC regimens either in combination with other alkylating agents or in rapidly cycled courses of HDC with SCT.
The use of high-dose chemotherapy (HDC) followed by autologous bone marrow transplantation (ABMT) has allowed encouraging response rates to be obtained in different adult and pediatric solid tumors. [1] [2] [3] A dose-effect relationship has been demonstrated with different alkylating agents such as melphalan 4 and thiotepa. multifunctional alkylating agent known to produce a significant anticancer effect in a variety of solid tumors. 2, 6 Encouraging results have previously been obtained in various pediatric tumors with high-dose alkylating agents. 1, 2, 7, 8 The aim of the present study was to investigate the potential benefits of high-dose thiotepa (HDT) in various refractory pediatric solid tumors.
Patients and methods

Patient characteristics
From 1987 to 1995, 22 children with refractory solid tumors were treated with HDT followed by autologous SCT in the Pediatrics Department of the Institut Gustave Roussy (see Table 1 ). Their median age at the time of the HDC was 8.5 years (range [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . The sex ratio was 1.5 boy/1 girl.
The tumor types in this series were rhabdomyosarcoma (eight), osteosarcoma (seven), neuroblastoma (three), Ewing's sarcoma (three) and Burkitt's lymphoma (one).
All patients had previously undergone extensive treatment prior to entry into this phase II study. They had all received conventional chemotherapy with three to 10 different drugs (median six). They had all previously received alkylating agents (cyclophosphamide or ifosfamide). Surgery which had been performed in 13 children, consisted of resection of the primary tumor in seven cases and of both the primary tumor and metastases in six. Four patients had also been treated with radiation therapy. One patient (rhabdomyosarcoma) received high-dose interleukin 2.
All patients had measurable disease at the time of the transplant.
Osteosarcoma patients were treated at diagnosis of the first to fifth emergence of metastases. All had measurable disease at metastatic sites; five had progressive disease (PD) and two were in partial remission (PR).
In patients with a rhabdomyosarcoma, disease was measurable at the site of the primary tumor (three patients), of the metastases (one patient) or at both sites (four patients). At the time of HDC, 5/8 patients had PD and three were in PR. Among these patients, four had never achieved complete remission (CR), the other four had relapsed one to three times.
Patients with Ewing's sarcoma had measurable disease at the site of metastases (one patient) or both a primary tumor and metastases (two patients). Two of them had never achieved CR (one had PD and one was in PR and the third was in second PR at the time of HDC). CR = complete remission; PR = partial remission; PD = progressive disease; R = refractory; S = sensitive; PT = primary tumor; Metast = metastases.
All three neuroblastoma patients had measurable primary and metastatic disease. None had ever achieved a complete remission, two were in PR and one had PD.
The patient with Burkitt's lymphoma received HDC while in first PR. Disease (primary tumor and metastases) was measurable.
Drug administration
Thiotepa was administered as a 1-h intravenous infusion at a daily dose of 300-350 mg/m 2 /day for 3 consecutive days (total dose of 900-1050 mg/m 2 ).
Transplantation procedures
Transplantation was performed at least 48 h after the end of chemotherapy. It consisted of an autologous bone marrow transplant in 17/22 children and peripheral blood stem cell (PBSC) transplant in four. PBSC were obtained by leukapheresis and mobilized by G-CSF (Neupogen; Amgen, Neuilly-sur-Seine, France) in steady state according to the protocol published by Sheridan et al. 9 
Supportive care
All patients were isolated in laminar air-flow single rooms and were fitted with right atrial catheters on admission to the transplant unit. They received parenteral nutrition and broad-spectrum antibiotics, as previously described. 10 Platelet and packed red cell transfusions were used to maintain a platelet count Ͼ50 × 10 9 /l and a hemoglobin level Ͼ70 g/l, respectively. All blood products were irradiated to a dose of 25 Gy before transfusion and CMV-seronegative patients were transfused with seronegative blood products. All patients grafted with PBSC and two with BM received G-CSF after transplantation.
Evaluation of toxicity
Neutrophil recovery was defined as a blood neutrophil count above 0.5 × 10 9 /l without G-CSF support. Platelet recovery was defined as a blood platelet count above 50 × 10 9 /l, independent of platelet transfusion. Visceral toxicity was evaluated according to the criteria defined by Bearman et al.
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Evaluation of tumor response
Tumor response was evaluated around day 35 post transplant.
CT scan or MRI were used to measure changes in the volume of all sarcomas. Neuroblastomas were evaluated with a CT scan for the primary tumor and an MIBG scan, urinary catecholamine metabolite determinations (HVA, VMA and dopamine). Bone marrow aspirates (10) and trephine biopsies (two) were used to evaluate metastatic disease. Burkitt's lymphoma was evaluated by bone marrow aspirate and cerebrospinal fluid analysis.
Partial response (PR) was defined as a more than 50% shrinkage of measurable disease. Stable disease (SD) corresponded to shrinkage to below 25% of the original volume. Progressions at any site including mixed responses, were classified as progressive disease (PD). PD DOD 1 PR = partial remission; PD = progressive disease; SD = stable disease; CR = complete remission; DOD = dead of disease; R×T = radiotherapy; Surg = surgery.
Results
All patients were evaluable for toxicity and tumor response.
Tumor response and survival
Details of tumor response are given in Table 2 .
A partial remission was observed in 50% (11/22) of the patients. Four of 22 had stable disease (SD) and 7/22 progressive disease (PD).
Of the seven patients with osteosarcoma, four achieved PR; there were two cases of SD and one of PD.
Surgery was performed for metastases in five patients (four PR and one SD) 2 months post SCT. A complete resection or a macroscopic incomplete resection of detectable metastases was performed in four and one patients, respectively. Percentage of viable residual cells observed in the resected tumor was documented: total necrosis of the tumor was observed in one patient with radiological evidence of SD and 5, 20, 20 and 90% of viable cells were observed in the four tumors, respectively. Surgical excision of metastases was performed in the patient with PD, 4 months post SCT (100% of viable cells were found). He died of disease progression, 8 months post SCT. Finally, among the 7 patients, four have died of disease progression and three are alive with NED 25 m+, 48 m+, 51 m+ post transplantation.
Four PRs were obtained in patients with rhabdomyosarcoma; disease was stable in two and progressed in the two remaining ones. Among the four responding patients, surgical excision of the tumor was performed in three, and viable cells were detected in all operative specimens. These three patients relapsed and died of disease progression (2 m, 13 m, 38 m). Radiotherapy was delivered to the primary tumor in the fourth patient. He is alive with NED 33 months post BMT.
Of the three children with Ewing's sarcomas, two achieved PR and one had PD. A second course of high-dose chemotherapy followed by transplantation was performed in the two responding patients. One relapsed 7 months after HDT and died, and the other is alive with NED 28 m+ after the first transplant.
One PR and two cases of PD were observed in the three patients with neuroblastoma. The patient with a PR received a second course of high-dose chemotherapy followed by an allogeneic transplant. He relapsed 8 months later and died of disease progression.
Disease progressed in the Burkitt's lymphoma after HDT.
As of December 1997, five patients are alive with NED with a follow-up of 35 m+, 38 m+, 43 m+, 58 m+ and 61 m+. Gastrointestinal toxicity: Digestive toxicity was moderate and consisted of vomiting in seven patients and prolonged nausea for a median duration of 8 days (range 1-10) in 10.
Grade I and II diarrhea was observed in 11 patients and seven children, respectively. Grade I stomatitis occurred in 9/22 patients, and grade II in seven.
Hepatic toxicity: Grade I hepatotoxicity was observed in 17 patients. It consisted of cytolysis (raised transaminase levels) in five patients, cholestasis in five, and both in seven patients.
One case of moderate hepatic veno-occlusive disease was observed, that resolved rapidly without treatment.
Skin toxicity: Cutaneous toxicity was moderate and consisted of acute erythrodermia in five patients. Secondary melanodermia was observed in eight patients.
Neurological toxicity: Five patients had intermittent tremor of the trunk and extremities for about 6 weeks.
No toxicity-related deaths occurred.
Discussion
Thiotepa is a multifunctional alkylating agent with a broad spectrum of activity. The maximum conventional dose is 65 mg/m 2 , with myelosuppression being a dose-limiting toxicity. 5 Dose escalation was not possible with the hematopoietic growth factor GM-CSF because of severe and cumulative platelet toxicity. 12 However, autologous bone marrow infusion allowed dramatic dose escalation, and the maximum tolerated dose was established at 1125 mg/m 2 but with digestive and central nervous system-limiting toxicities. 3 In our unit, 7 the optimal dose of thiotepa was considered to be 900 mg/m 2 , and is the usual dose currently administered with hematopoietic support.
In order to improve the prognosis of refractory malignant diseases in children, we have developed several protocols using alkylating agents, since a dose-effect relationship has been demonstrated to be particularly apparent with this family of drugs. 13, 14 A dose-effect relationship has been demonstrated in vitro in various childhood solid tumor cell lines 15 and pharmacokinetic data on these drugs have been extensively studied. 5 Thiotepa and its major metabolite, tepa, attain CSF concentrations which are roughly equivalent to simultaneous plasma concentrations. 16 The overall response rate observed in the present study was 50% and was similar to that observed by Saarinen et al 1 in a smaller series, in which only seven patients could be evaluated, of whom two achieved CR and three PR. The median duration of response in our study was 7 months with 6/22 patients (27%) alive with NED more than 1 year after HDT. Such long-lasting responses after HD single agent chemotherapy in a phase II study were also observed by Saarinen with a median event-free survival of 9 months. The response rate and the long-lasting disease-free survival observed in patients with osteosarcoma are particularly encouraging. Indeed, of the seven children with osteosarcoma, three are alive with no evidence of disease with a follow-up of 25-51 months. In Saarinen's study, a partial response was observed in the only patient with osteosarcoma.
With the advent of aggressive chemotherapy, the prognosis for patients with malignant osteosarcoma has improved considerably. However, despite the success attained with combined surgery and chemotherapy, about 30% of patients develop metastases or a local recurrence. Some can still be cured with conventional treatment. We previously published a study in which prognostic factors were analyzed in osteosarcoma patients. 17 All patients included in the present study had at least one poor-risk factor and could not be cured by conventional therapies. The high response rate (50%) is very encouraging and furthermore, 3/5 long-term survivors are still in remission. Among them, two patients had metastases at diagnosis and had relapsed at least once.
Rhabdomyosarcoma are chemosensitive tumors and long-term survival in localized tumors is 60% in European studies. 18 Similar results have been published in American series. 19 However, in high-risk groups, patients with parameningeal or metastatic disease have a very poor prognosis. [18] [19] [20] [21] Phase II studies of high-dose single agents are rare. HD-melphalan 22 and HD-etoposide 23 yield acceptable response rates, with 44% and 42% of PRs in rhabdomyosarcoma, respectively. However, the benefits gained with these agents in terms of long-term survival have yet to be demonstrated. HD-melphalan used as consolidation therapy for metastatic rhabdomyosarcoma proved disappointing. 18 New therapeutic approaches for these poor-risk patients need to be investigated. The results of our phase II study of HDT are very encouraging since among the eight children, four (50%) PRs were observed. HDT should be considered a potent treatment for metastatic rhabdomyosarcoma in future schedules.
Results of conventional chemotherapy are poor in patients with metastatic Ewing's sarcoma. 24, 25 High-dose chemotherapy has been demonstrated to improve the prognosis of these patients. 26 The phase II study of HDT requires a larger accrual to determine whether this drug is effective in Ewing's sarcomas.
Toxicity of HDT was moderate and similar to that observed in adult patients. 2, 27 No toxicity-related deaths occurred. In the Saarinen study three toxicity-related deaths were observed, two after a second course of HDT. All these deaths were due to septic complications. No severe neurological toxicity was observed, confirming that 1000 mg/m 2 seems to be the threshold above which neurological toxicity is likely to occur. 2, 3 As the toxicity of this conditioning regimen is relatively mild, HDT could be used in combination with HD regimens in children with refractory solid tumors, as already attempted in children with brain tumors. In fact, when a poor response rate was observed at conventional doses in malignant brain tumors in children, 8 HDT was used in combination with either busulfan 7, 28, 29 or VP 16 30 and followed by bone marrow transplant. Very high response rates were obtained especially in medulloblastomas. Brochstein et al 31 used a conditioning regimen with a combination of etoposide, thiotepa and cyclophosphamide followed by ABMT in six children with solid tumors, and toxicity was acceptable. 31 With the development of peripheral hematopoietic stem cell support it is now possible to perform repeated highdose chemotherapies. This strategy is already employed in patients with metastatic breast cancer. 32, 33 The rationale behind this strategy is that the dose can be intensified while hematopoietic toxicity is circumvented by SCT. Thiotepa could prove strategic in tumors such as sarcomas in which its efficacy has been demonstrated. We are currently developing this therapeutic approach in metastatic neuroblastoma and medulloblastoma. 34 Visceral toxicity will be the limiting factor in such schedules.
In conclusion, this study demonstrates that thiotepa is a very effective treatment for refractory childhood tumors and particularly sarcomas, with a response rate of 50%. The long-lasting responses are very encouraging. The mild toxicity makes this alkylating agent a valid candidate either in combination regimens or in sequential high-dose chemotherapy with peripheral blood stem cell support strategies.
